ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. More Details
High growth potential with imperfect balance sheet.
Share Price & News
How has ThermoGenesis Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: THMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: THMO's weekly volatility (9%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: THMO underperformed the US Medical Equipment industry which returned 30.8% over the past year.
Return vs Market: THMO underperformed the US Market which returned 37.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ThermoGenesis Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
3 months ago | Simply Wall StWhen Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
7 months ago | Simply Wall StDoes ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Is ThermoGenesis Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate THMO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate THMO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: THMO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: THMO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate THMO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: THMO is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (4.5x).
How is ThermoGenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THMO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: THMO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: THMO's is expected to become profitable in the next 3 years.
Revenue vs Market: THMO's revenue (25.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: THMO's revenue (25.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if THMO's Return on Equity is forecast to be high in 3 years time
How has ThermoGenesis Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: THMO is currently unprofitable.
Growing Profit Margin: THMO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: THMO is unprofitable, but has reduced losses over the past 5 years at a rate of 11.6% per year.
Accelerating Growth: Unable to compare THMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THMO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).
Return on Equity
High ROE: THMO has a negative Return on Equity (-139.97%), as it is currently unprofitable.
How is ThermoGenesis Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: THMO's short term assets ($16.9M) exceed its short term liabilities ($10.5M).
Long Term Liabilities: THMO's short term assets ($16.9M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: THMO's debt to equity ratio (70.3%) is considered high.
Reducing Debt: THMO's debt to equity ratio has increased from 4.3% to 70.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: THMO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: THMO has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.4% each year.
What is ThermoGenesis Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THMO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of THMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Xu (50 yo)
Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph.D., is the Founder, Chairman and Chief Executive Officer of Boyalife Group since July 2009. He serves as an Advisor at WI Harper Group. Dr. Xu has been the C...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD2.00M) is above average for companies of similar size in the US market ($USD545.22K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
Experienced Management: THMO's management team is considered experienced (4.2 years average tenure).
Experienced Board: THMO's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 87.3%.
ThermoGenesis Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ThermoGenesis Holdings, Inc.
- Ticker: THMO
- Exchange: NasdaqCM
- Founded: 1986
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$26.802m
- Shares outstanding: 11.91m
- Website: https://www.thermogenesis.com
Number of Employees
- ThermoGenesis Holdings, Inc.
- 2711 Citrus Road
- Rancho Cordova
- United States
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions fo...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/28 02:15|
|End of Day Share Price||2021/07/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.